Synthesis and biological evaluation of small molecule modulators of CDK8/Cyclin C complex with phenylaminoquinoline scaffold

Mohammad M. Al-Sanea 1

1 Pharmaceutical Chemistry Department, College of Pharmacy, Jouf University, Sakaka, Aljouf, Saudi Arabia

Corresponding Author: Mohammad M. Al-Sanea
Email address: mmalsanea@ju.edu.sa

Background. CDK8/CycC complex has kinase activity towards the carboxyterminal domain of RNA polymerase II, and contributes to the regulation of transcription via association with the mediator complex. Different human malignancies, mainly colorectal and gastric cancers, were produced as a result of overexpression of CDK8/CycC in the mediator complex. Therefore, CDK8/CycC complex represents as a cancer oncogene and it has become a potential target for developing CDK8/CycC modulators.

Methods. A series of nine 4-phenylaminoquinoline scaffold-based compounds 5a-i were synthesized, and biological evaluation of this series was performed as potential inhibitors of CDK8/CycC complex.

Results. The scaffold substituent effects on the intrinsic inhibitory activity toward CDK8/CycC complex are addressed trying to present a novel outlook of CDK8/CycC Complex inhibitors with 4-phenylaminoquinoline scaffold in cancer therapy. The secondary benzenesulfonamide analogues proved to be the most potent compounds in suppressing CDK8/CycC enzyme, whereas, their primary benzenesulfonamide analogues showed inferior activity. Moreover, the benzene reversed sulfonamide analogues were totally inactive.

Discussion. The titled scaffold showed promising inhibitory activity data and there is a crucial role of un/substituted sulfonamido group for CDK8/CycC complex inhibitory activity. Compound 5d showed submicromolar potency against CDK8/CycC (IC_{50} = 0.639 μM) and it can be used for further investigations and to design another larger library of phenylaminoquinoline scaffold-based analogues in order to establish detailed SARs.
Synthesis and Biological Evaluation of small molecule modulators of CDK8/Cyclin C Complex with Phenylaminoquinoline Scaffold

Mohammad Mahmoud Al-Sanea

Pharmaceutical Chemistry Department, College of Pharmacy, Jouf University, Sakaka, Aljouf 2014, Saudi Arabia

Corresponding Author:
Mohammad Al-Sanea
Pharmaceutical Chemistry Department, College of Pharmacy, Jouf University, Sakaka, Aljouf 2014, Saudi Arabia
Email address: mmalsanea@ju.edu.sa

Abstract

Background. CDK8/CycC complex has kinase activity towards the carboxyterminal domain of RNA polymerase II and contributes to the regulation of transcription via association with the mediator complex. Different human malignancies, mainly colorectal and gastric cancers, were produced as a result of overexpression of CDK8/CycC in the mediator complex. Therefore, CDK8/CycC complex represents a cancer oncogene and it has become a potential target for developing CDK8/CycC modulators.

Methods. A series of nine 4-phenylaminoquinoline scaffold-based compounds 5a-i were synthesized, and the biological evaluation of this series was performed as potential inhibitors of CDK8/CycC complex.

Results. The scaffold substituent effects on the intrinsic inhibitory activity toward CDK8/CycC complex are addressed trying to present a novel outlook of CDK8/CycC Complex inhibitors with 4-phenylaminoquinoline scaffold in cancer therapy. The secondary benzenesulfonamide analogues proved to be the most potent compounds in suppressing CDK8/CycC enzyme, whereas, their primary benzenesulfonamide analogues showed inferior activity. Moreover, the benzene reversed sulfonamide analogues were inactive.

Discussion. The titled scaffold showed promising inhibitory activity data and there is a crucial role of un/substituted sulfonamido group for CDK8/CycC complex inhibitory activity. Compound 5d showed submicromolar potency against CDK8/CycC (IC_{50} = 0.639 μM) and it can be used for further investigations and to design another larger library of phenylaminoquinoline scaffold-based analogues to establish detailed SARs.
Introduction
Cyclin-dependent kinases (CDKs) drive cell cycle through phosphorylation of a variety of vital substrates (Satyanarayana & Kaldis 2009). Association of CDKs with regulatory partners (cyclins) regulates CDKs activity (Obaya & Sedivy 2002). Therefore, several cyclin/kinase complexes have been considered as essential for controlled cell proliferation (Sears & Nevins 2002). Cyclin C is known to form a stable complex with CDK8 (CDK8/CycC complex). The kinase active complex is associated with direct phosphorylation activity towards gene-specific transcription factors, thus controls their downstream function (Nemet et al. 2014). Hence, CDK8/CycC can modulate transcriptional output from distinct transcription factors involved in oncogenic control (Malik & Roeder 2005). Recent evidence supports the idea that mediator complex-associated CDK8/CycC has been involved in the regulation of multiple transcription pathways and implicated as an oncogene in colorectal and gastric cancers through activation of WNT signaling (Kim et al. 2006; Rzymski et al. 2015). CDK8 is amplified and overexpressed in colon, gastric, breast cancers and melanoma (Li et al. 2014a; Roninson et al. 2019). Accordingly, CDK8/CycC complex may represent a potential drug target for different kinds of human malignancies with reduced toxic effects on normal cells (Chen et al. 2019; He et al. 2019; Rzymski et al. 2015; Sánchez-Martínez et al. 2019; Schneider et al. 2013). Moreover, CDK8/CycC complex plays several roles in modulating gene expression levels (Firestein et al. 2008; Knuesel et al. 2009a; Knuesel et al. 2009b; Li et al. 2014b).

Even though CDK inhibitors have been abundantly described, attempts of discovering selective CDK8 inhibitors have emerged as a promising strategy for cancer therapy as Pan-CDK inhibitor has shown narrow therapeutic window and potential risks (Al-Sanea et al. 2015; Al-Sanea et al. 2016b; Al-Sanea et al. 2015; Firestein et al. 2008; Kapoor et al. 2010; Xu & Ji 2011). Such selective inhibitors allow cancer therapy by reducing mitogenic signals in several cancer cells (Adler et al. 2012; McDermott et al. 2017; Rzymski et al. 2015).

Several chemical scaffold-based small molecules have been applied for the design of CDK8 inhibitors. Among these scaffolds, quinoline and its bioisosteres have successively shown potent modulation of CDK8 activity. The steroidal natural product cortistatin A, which has quinoline moiety as a hinge component and steroidal core responsible for extensive intermolecular forces with the ATP-binding cavity, showed a highly potent ATP-competitive CDK8 inhibitory activity (IC$_{50}$ = 15 nM) that exhibited anticancer activity in animal models of acute myeloid leukemia (AML) (Cee et al. 2009; Crown 2017; Pelish et al. 2015; Rzymski et al. 2017). Senexin B with 4-aminoquinazoline scaffold showed potent CDK8 modulation with an IC$_{50}$ value of 24 nM (McDermott et al. 2017; Rzymski et al. 2015). In 2016, Schiemann et al. described new potent and selective CDK8 ligands with benzylindazole scaffold that showed an IC$_{50}$ value against CDK8 of 10 nM (Schiemann et al. 2016). Besides, many well-known kinase ligands such as sorafenib and imatinib represent another type of potent CDK8 inhibitors with different binding modes (Chen et al. 2019; Schneider et al. 2011).
It is noteworthy that the kinase activity of CDK8 is affected by substrate binding and association with other mediator complex members as well. By utilizing a scaffold hopping strategy on the aforementioned quinoline isosteres, a series of new phenylaminoquinoline derivatives with sulphonamide moiety at position 3 in terminal phenyl ring was designed, synthesized and pharmacologically evaluated as potential small molecule modulators of CDK8/CycC complex.

**Materials & Methods**

All chemical reagents and solvents were of analytical grade, purchased from commercial suppliers (Sigma-Aldrich and Alfa-aesar) and utilized to accomplish this work as received. All reactions were carried out in a dry nitrogen atmosphere. The microwave-assisted synthesis was carried out in a Biotage Initiator apparatus operating in single mode, the microwave cavity producing controlled irradiation at 2.45 GHz (Biotage AB, Uppsala, Sweden). The reactions were run in sealed vessels. These experimentations were carried out by employing magnetic stirring and a fixed hold time applying variable power to reach (during 1–2 min) and then keep the desired temperature in the vessel for the preset time. On the reactor vial glass, an IR sensor was applied to monitor the temperature. The NMR spectra were obtained on Bruker Avance 400 (400 MHz $^1$H and 100.6 MHz $^{13}$C NMR). Column chromatography was performed on Merck Silica Gel 60 (230–400 mesh). Thin layer chromatography (TLC) was performed using sheets pre-coated with silica gel 60 F254 supplied from Merck. The purity of compounds was determined by analytical high performance liquid chromatography (HPLC) using a Water ACQUITY UPLC (CORTECSTM) with C18 column (2.1 mm x 100 mm; 1.6 μm) at 40 °C. HPLC data were noted using parameters as follows: 0.1% formic acid in water and 0.1% formic acid in methanol and flow rate of 0.3 mL/min. Waters ACQUITY UPLC BEH C18 1.7 μ-Q-TOF SYNAPT G2-Si High Definition Mass Spectrometry was used to obtain high-resolution spectra. Compounds 3-4 and 5a-c, i were previously reported (Al-Sanea et al. 2019).

**Common procedures for the synthesis of key intermediates 4a–d.**

A solution of intermediated 3a–d (1.0 mmol) in POCl$_3$ (6 mL) was refluxed for 1 h. Evaporation of the mixture was performed in vacuo and the residue was extracted with methylene chloride, aqueous ammonia, and crushed ice. The methylene chloride layer was dried over anhydrous Na$_2$SO$_4$ and concentrated. Column chromatography (SiO$_2$, EA : n-Hex) was applied to purify the residue to get compounds 4a-c (Scheme 1).

**Common procedures for the synthesis of the target compounds 5a-i**

To a microwave vial, were sequentially added the appropriate intermediated 4a-c (0.21 mmol), 3-amino-N-methylbenzenesulfonamide (0.04 gm, 0.21 mmol), or N-(3-phenyl)methanesulfonamide (0.04 gm, 0.21 mmol), 3-aminobenzenesulfonamide (0.036 gm, 0.21 mmol), and absolute ethyl alcohol (12 mL). The microwave vial was sealed and heated under microwave conditions at 150 °C for 30 min. The reaction mixture was evaporated in vacuo and the residue was extracted with ethyl acetate and NaHCO$_3$ (aq). The ethyl acetate layer was
dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography (SiO₂, EA: n-Hex) to provide quinolines 5a-i (Scheme 1).

**Ethyl 6-Bromo-4-(3-sulfamoyl-phenylamino)-quinoline-3-carboxylate (5a)**

Yellow solid, yield: 71%, mp: 235.6–237.2 °C; 1H NMR (DMSO-d₆, 400 MHz) δ ppm: 1.07 (t, 3H, J = 6.8 Hz, CH₃), 7.33 (s, 3H, OCH₃), 3.99 (q, 2H, J = 6.8 Hz, CH₂CH₃), 7.14-7.16 (m, 1H, phenyl H-2), 7.33 (s, 2H, phenyl H-4), 7.42-7.48 (m, 5H, phenyl H-5,6, quinoline H-5,7,8), 7.94 (m, 1H, quinoline H-5), 8.40 (s, 1H, quinoline H-8), 8.92 (s, 1H, NH); 13C NMR (DMSO-d₆, 100 MHz): 14.22 (CH₃), 77.45-77.51 (m, 3H), 7.94 (s, 2H), 8.53 (s, 1H), 9.71 (s, 1H, NH); 1H NMR (DMSO-d₆, 400 MHz): 1.07 (t, 3H, J = 6.8 Hz, CH₃), 7.17 (s, 1H), 7.36 (s, 2H, CH₂), 7.91-7.93 (m, 1H, quinoline H-8), 8.25 (d, 1H J = 7.6 Hz, quinoline H-7), 8.91 (s, 1H, SO₂NH), 9.68 (s, 1H, NH); 13C NMR (DMSO-d₆): 14.22 (CH₃), 77.45-77.51 (m, 3H), 7.94 (s, 2H), 8.53 (s, 1H), 9.71 (s, 1H, NH).

**Ethyl 6-Methoxy-4-(3-sulfamoyl-phenylamino)-quinoline-3-carboxylate (5b)**

Yellow solid, yield: 65%, 1H NMR (DMSO-d₆, 400 MHz at 298 K): 1.13 (t, 3H, J = 6.8 Hz, CH₃), 3.73 (s, 3H, OCH₃), 3.99 (q, 2H, J = 6.8 Hz, CH₂CH₃), 7.14-7.16 (m, 1H, phenyl H-2), 7.33 (s, 2H, phenyl H-4), 7.42-7.48 (m, 5H, phenyl H-5,6, quinoline H-5,7,8), 7.91-7.93 (m, 1H, quinoline H-2), 8.84 (s, 1H, NH); 1H NMR (DMSO-d₆, 400 MHz): 1.13 (t, 3H, J = 6.8 Hz, CH₃), 3.73 (s, 3H, OCH₃), 3.99 (q, 2H, J = 6.8 Hz, CH₂CH₃), 7.17 (s, 1H), 7.36 (s, 2H, CH₂), 7.94 (m, 1H, quinoline H-5), 8.40 (s, 1H, quinoline H-8), 8.92 (s, 1H, NH); 13C NMR (DMSO-d₆): 14.22 (CH₃), 77.45-77.51 (m, 3H), 7.94 (s, 2H), 8.53 (s, 1H), 9.71 (s, 1H, NH); 1H NMR (DMSO-d₆, 400 MHz): 1.13 (t, 3H, J = 6.8 Hz, CH₃), 3.73 (s, 3H, OCH₃), 3.99 (q, 2H, J = 6.8 Hz, CH₂CH₃), 7.17 (s, 1H), 7.36 (s, 2H, CH₂), 7.94 (m, 1H, quinoline H-5), 8.40 (s, 1H, quinoline H-8), 8.92 (s, 1H, NH); 13C NMR (DMSO-d₆): 14.22 (CH₃), 77.45-77.51 (m, 3H), 7.94 (s, 2H), 8.53 (s, 1H), 9.71 (s, 1H, NH).
122.53 (quinoline C-10), 123.04 (quinoline C-6), 126.69 (quinoline C-5), 130.56
(benzenesulfonamide C-5), 132.14 (quinoline C-8), 134.75 (quinoline C-7), 140.80
(benzenesulfonamide C-3), 144.35 (benzenesulfonamide C-1), 146.54 (quinoline C-2), 148.95
(quinoline C-9), 152.03 (quinoline C-4), 166.34 (C=O); HRESI-MS m/z calcd for [M+H]^+
C_{19}H_{19}BrN_{3}O_{4}S: 464.0280, found: 464.0273.

Ethyl 6-methoxy-4-((3-methylsulfonamido)phenylamino)quinoline-3-carboxylate (5e)
Yellow solid, yield: 64%, H NMR (DMSO-d_6, 400 MHz at 298 K): 1.17 (t, 3H, J = 7.2 Hz, CH_2,
CH_3), 2.96 (s, 3H, SO_2CH_3), 3.71 (s, 3H, OCH_3), 3.99 (q, 2H, J = 7.2 Hz, CH_2CH_3), 6.75-6.77
(m, 1H, phenyl H-2), 6.88-6.90 (m, 2H, phenyl H-4,6), 7.22-7.26 (m, 1H, phenyl H-5), 7.40-7.45
(m, 2H, quinoline H-5,7), 7.89 (d, J = 8 Hz, 1H, quinoline H-8), 8.80 (s, 1H, quinoline H-2),
152.03 (quinoline C-4), 166.90 (C=O); HRESI-MS m/z calcd for [M+H]^+
C_{19}H_{19}BrN_{3}O_{4}S: 464.0280, found: 464.0273.

Ethyl 7-chloro-6-fluoro-4-((3-(methylsulfonamido)phenylamino)quinoline-3-carboxylate (5f)
Yellow solid, yield: 55%, H NMR (DMSO-d_6, 400 MHz at 298 K): 1.12 (t, 3H, J = 6.8 Hz, CH_2,
CH_3), 2.99 (s, 3H, SO_2CH_3), 3.92 (q, 2H, J = 6.8 Hz, CH_2CH_3), 6.77 (d, 1H, J = 8 Hz, phenyl H-
2), 6.90-6.93 (m, 2H, phenyl H-4,6), 7.23-7.27 (m, H, phenyl H-5), 8.12 (d, 1H, J = 11.2 Hz,
quinoline H-7), 8.21 (d, J = 6 Hz, 1H, quinoline H-8), 8.87 (s, 1H, quinoline H-2), 9.63 (s, 1H,
SO_2NH), 9.79 (s, 1H, NH); HRESI-MS m/z calcd for [M+H]^+
C_{19}H_{17}ClFN_{3}O_{4}S: 438.0691, found: 438.0687.

Ethyl 6-Bromo-4-(3-methanesulfonylphenylamino)-quinoline-3-carboxylate (5g)
Yellow solid, yield: 67%, mp: 183.4−184.5 °C, H NMR (DMSO-d_6, 100 MHz) 8 ppm: 1.12 (t, 3H, J = 7.2 Hz, CH_2,
CH_3), 2.95 (s, 3H, SO_2CH_3), 3.93 (q, 2H, J = 7.2 Hz, CH_2CH_3), 6.78 (s, 1H, phenyl H-2), 6.91-6.94 (m, 2H, phenyl H-4,6), 7.24 (m, 1H, phenyl H-5), 7.90 (m, 2H, quinoline H-5,7), 8.40 (m, 1H, quinoline H-8), 8.88 (s, 1H, quinoline H-2), 9.67 (s, 1H, NH); HRESI-MS m/z calcd for [M+H]^+
C_{19}H_{17}ClFN_{3}O_{4}S: 438.0691, found: 438.0691.

Ethyl 6-methoxy-4-((3-(methylsulfonamido)phenylamino)quinoline-3-carboxylate (5h)
Yellow solid, yield: 62%. $^1$H NMR (DMSO-$d_6$, 400 MHz at 298 K): 1.13 (t, 3H, $J = 7.2$ Hz, CH$_2$CH$_3$), 2.39 (s, 3H, NHCH$_3$), 3.75 (s, 3H, OCH$_3$), 3.99 (q, 2H, $J = 7.2$ Hz, CH$_2$CH$_3$), 7.24 (d, 1H, $J = 7.6$ Hz, phenyl H-2), 7.36-7.52 (m, 6H, phenyl H-4,5,6, quinoline H-5,7,8), 7.95 (s, 1H, quinoline H-2), 8.85 (s, 1H, SO$_2$NH), 9.57 (s, 1H, NH); $^{13}$C NMR (DMSO-$d_6$): 14.28 (CH$_2$CH$_3$), 28.99 (NHCH$_3$), 55.91 (OCH$_3$), 61.35 (CH$_2$CH$_3$), 103.47 (quinoline C-5), 111.69 (phenyl C-2), 117.23 (phenyl C-4), 120.47 (phenyl C-6), 122.39 (quinoline C-3), 122.52 (quinoline C-10), 123.73 (quinoline C-7), 130.49 (phenyl C-5), 131.60 (quinoline C-8), 140.72 (quinoline C-9), 144.77 (phenyl C-3), 146.17 (phenyl C-1), 146.50 (quinoline C-2), 148.92 (quinoline C-3), 157.54 (quinoline C-6), 166.86 (C=O); HRESI-MS m/z calcd for [M+H]$^+$ C$_{20}$H$_{21}$N$_3$O$_5$S: 416.1280, found: 416.1277.

Ethyl 7-chloro-6-fluoro-4-((3-(methylsulfonyl)phenyl)amino)quinoline-3-carboxylate (5i)

Yellow solid, yield: 58%. $^1$H NMR (DMSO-$d_6$, 400 MHz at 298 K): 1.07 (t, 3H, $J = 6.8$ Hz, CH$_2$CH$_3$), 2.40 (s, 3H, NHCH$_3$), 3.90 (q, 2H, $J = 6.8$ Hz, CH$_2$CH$_3$), 7.27 (d, 1H, $J = 7.6$ Hz phenyl H-2), 7.41 (s, 1H, phenyl H-5), 7.49-7.53 (m, 2H, phenyl H-4,6), 8.19 (d, 1H, $J = 11.6$ Hz quinoline H-7), 8.26 (d, 1H, $J = 7.2$ Hz quinoline H-8), 8.91 (s, 1H, quinoline H-2), 9.70 (s, 1H, SO$_2$NH), 9.79 (s, 1H, NH); $^{13}$C NMR (DMSO-$d_6$): 14.19 (CH$_2$CH$_3$), 29.00 (NHCH$_3$), 61.52 (CH$_2$), 110.18, 110.42 (phenyl C-2), 111.56, 117.44 (phenyl C-4), 121.17, 121.25 (phenyl C-6), 121.33 (quinoline C-10), 122.63 (quinoline C-8), 125.22, 125.43, 130.61 (phenyl C-5), 131.58, 140.89, 144.09 (phenyl C-3), 146.97 (phenyl C-1), 147.02 (quinoline C-2), 147.54 (quinoline C-5), 152.26 (quinoline C-3), 153.76 (quinoline C-7), 156.21 (quinoline C-6), 166.24 (C=O); HRESI-MS m/z calcd for [M+H]$^+$ C$_{19}$H$_{17}$Cl FN$_3$O$_4$S: 438.0691, found: 438.0693.

**In vitro kinase inhibition assay**

Reaction Biology Corp. Kinase HotSpotSM service (http://www.reactionbiology.com) was used for the screening of tested compounds. Kinase Profiling is a 10 dose IC$_{50}$ singlet assay. Activity of kinases were assessed by the HotSpot assay platform, which contained specific kinase/substrate pairs along with required cofactors (Abdelazem et al. 2015; Abdelazem et al. 2016; Al-Sanea et al. 2015; Al-Sanea et al. 2013; Park et al. 2014).

**Docking studies**

Molecular Operating Environment (MOE version 2008.10) by Chemical Computing Group (CCG) was used for the docking studies (Inc. 2016). The protein preparation steps involved 3D protonation, energy minimization, and active site identification. The X-ray crystallographic structure of CDK8/CycC enzyme co-crystallized with Senexin A (PDB code 4f7s) was obtained from the Protein Data Bank (Schneider et al. 2013). The enzyme was prepared for virtual docking studies where: (i) the ligand molecule with any existing solvent molecules were removed. (ii) Hydrogen atoms were added to the structure with their standard geometry. To visualize the binding pocket, alpha spheres were created followed by the generation of dummy atoms on the centers of these spheres. The pocket was found to be a deep cavity lined with the
The methods followed for the synthesis of the target compounds 5a-i are represented in Scheme 1. Anilines 1a–c were firstly refluxed in ethanol with diethyl ethoxymethylene malonate to provide substituted phenylaminomethylene malonates 2a–c. Compounds 2a-c were cyclized thermally in diphenyl ether to the corresponding 4-oxo-1,4-dihydroquinolines 3a–c. Under the anhydrous condition, quinolines 3a–c were chlorinated via heating with excess of POCl₃ to provide the key intermediates 4a–c, as reported previously (Al-Sanea et al. 2019; Medapi et al. 2015; Rivilli et al. 2018). The target compounds 5a–i were achieved through microwave-assisted nucleophilic substitution reaction of 3-amino-N-methylbenzenesulfonamide, 3-aminobenzenesulfonamide and N-(3-phenyl)methanesulfonamide with the appropriate key intermediate 4a–c in ethanol (Al-Sanea et al. 2019).

CDK8/CycC complex inhibition

The newly prepared phenylaminoquinolines 5a–i were biologically evaluated as potential CDK8/CycC complex inhibitors. The percentage enzyme inhibition and half-maximal inhibitory concentration data of the target compounds with phenylaminoquinoline core structure and Staurosporine (as a standard inhibitor) against CDK8/CycC are summarized in Table 1.

Molecular docking

For designing CDK8/CycC type I inhibitor, targeting the hinge residue is essential to inhibit the kinase activity of the complex. To visualize the binding interactions between the promising biologically active compound 5d, we obtained a co-crystal structure of 6-isocyano-N-phenethylnquinazolin-4-amine (Senexin A ) in complexation with CDK8:Cyclin C with the DMG motif in the “in” conformation at 2.2 Å resolution (PDB : 4F7S).

Discussion

Chemistry
Based on $^1$H-NMR, $^{13}$C-NMR spectroscopic data and high-resolution mass spectroscopy (HRMS), the structures of all newly synthesized compounds were confirmed. $^1$HNMR spectra of all finals 5a-i showed new characteristic signals at $\delta$ 7.33–7.37 ppm, and 9.68–10.25 ppm corresponding to NH$_2$ and NH groups, respectively, that distinguished the finals 5a-i from chloroquinolines 4a-c. For compound 5d, three characteristic signals at $\delta$ 2.42, 8.94, and 9.64 ppm were displayed and assigned to -NHCH$_3$, -SO$_2$NH- and -NH- protons, respectively.

### CDK8/CycC complex inhibition

According to the inhibition data stated in Table 1, the following structure-activity relationship (SAR) notes are described as follows.

The methanesulphonamide analogue 5d showed maximal potency among all final compounds with submicromolar activity and IC$_{50}$ value of 0.639 $\mu$M, whereas, the corresponding primary benzenesulphonamide analogue 5a exhibited a 6-fold decrease in potency (IC$_{50}$ = 3.98 $\mu$M). On the contrary, the corresponding substituted benzenesulphonamide analogue (5g) exhibited no CDK8/CycC complex inhibitory activity, confirming the crucial role of PKa values of sulfonamide groups for the intrinsic activity of pharmacophore of the phenylaminoquinoline scaffold–based compounds. Moreover, the primary benzenesulphonamide analogues (5a & 5b) exhibited single digit micromolar potency in inhibiting the CDK8/CycC. Whereas, methanesulphonamide analogues (5d & 5e) showed superior potency with IC$_{50}$ values of 0.639 and 1.42 $\mu$M, respectively. Noteworthy, all 7-chloro-6-fluoro substituted quinolines (5c, 5f, 5i) failed to inhibit the CDK8/CycC enzyme, signifying the remarkable adverse effects of some quinoline substituents on the binding interaction, and hence the intrinsic activity. Therefore, concerning the influence of substitution of the quinoline moiety, the inhibitory activities increased in the order of 7-Cl-6-F < 6-OCH$_3$ < 6-Br.

### Molecular docking

The virtual docking study showed how the compound 5d in the 3D docking pose can anchor in the kinase deep pocket and extended with diverse functional groups toward the hinge region and the front pocket. Two direct hydrogen bonds are formed between the inhibitor 5d and the kinase domain of CDK8/CycC. The quinoline N forms an essential single H-bond with the backbone nitrogen of Ala100CDK8 on the hinge region. The sulfonyl O forms the second direct H-bond to the backbone N of Asp173CDK8 of the DMG motif. Moreover, $\pi$–$\pi$ stacking interaction with the gatekeeper residue (Phe97CDK8) and VDW interactions with several residues at the ATP binding pocket (Ala172CDK8, Ala50CDK8, Val27CDK8, Leu158CDK8, Val35CDK8, Tyr99CDK8, Ile79CDK8) were shown as depicted in Figure 1.

### Conclusions

...
We have demonstrated a new series of phenylaminoquinoline core structure-based compounds 5a-i have been synthesized and biologically evaluated as potential CDK8/CycC inhibitors. The methanesulfonamide analogues (5d & 5e) proved to be the most potent compounds in suppressing CDK8/CycC enzyme, whereas, the un/substitutes benzenesulfonamide analogues showed inferior (or no) activity, demonstrating the advantage of highly acidic NH of sulfonamide moiety. Careful selection of quinoline moiety substituents is highly recommended, as 7-chloro-6-fluoro bearing analogues (5c & 5f) showed no inhibition. Moreover, the secondary benzenesulfonamide analogues should be avoided, as they showed no inhibitory activities. We have discovered the most potent analogue 5d with submicromolar potency against CDK8/CycC (IC\textsubscript{50} = 0.639 μM) and it can be prepared in four steps with an overall yield of 64 % making it suitable for further investigations. Larger library of phenylaminoquinoline scaffold-based analogues are going to be prepared by our team to establish detailed and distinguished SARs.

In summary, the novel ((3-(N-methylsulfamoyl)phenyl)amino)quinoline derivatives exhibited potent CDK8/CycC inhibitory activity. Developing inhibitors targeting CDK8/CycC offers an exciting approach for treatment of human carcinomas.

Acknowledgments

I would like to express my special appreciation and thanks to my colleague Dr. Ahmed Elkamhawy, you have been a great research collaborator for me in this project.

References

Abdelazem AZ, Al-Sanea MM, Park BS, Park HM, Yoo KH, Sim T, Park JB, Lee S-H, and Lee SH. 2015. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors. *European journal of medicinal chemistry* 90:195-208.

Abdelazem AZ, Al-Sanea MM, Park H-M, and Lee SH. 2016. Synthesis of new diarylamides with pyrimidinyl pyridine scaffold and evaluation of their anti-proliferative effect on cancer cell lines. *Bioorganic & medicinal chemistry letters* 26:1301-1304.

Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM, and Firestein R. 2012. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. *Cancer research* 72:2129-2139.

Al-Sanea M, Abdelazem A, Park B, Yoo K, Sim T, Kwon Y, and Lee S. 2016a. ROS1 kinase inhibitors for molecular-targeted therapies. *Current medicinal chemistry* 23:142-160.

Al-Sanea M, Elkamhawy A, Zakaria A, Park B, Kwon Y, Lee S, Lee S, and Kim I, 2015. Synthesis and in vitro screening of phenylbipyridinylpyrazole derivatives as potential antiproliferative agents. *Molecules* 20:1031-1045.

Al-Sanea MM, Abdelazem AZ, Park BS, Yoo KH, Sim T, Kwon YJ, and Lee SH. 2016b. ROS1 Kinase Inhibitors for Molecular-Targeted Therapies. *Curr Med Chem* 23:142-160.

Al-Sanea MM, El-Deeb IM, and Lee SH. 2013. Design, synthesis and in vitro screening of new 1H-pyrazole and 1, 2-isoxazole derivatives as potential inhibitors for ROS and MAPK14 kinases. *Bull Korean Chem Soc* 34:437.

Al-Sanea MM, Elkamhawy A, Paik S, Bua S, Ha Lee S, Abdelgawad MA, Roh EJ, Eldehna WM, and Supuran CT. 2019. Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino) benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors. *Journal of enzyme inhibition and medicinal chemistry* 34:1457-1464.
Al-Sanea MM, Park BS, Abdelazem AZ, Selim KB, Yoo KH, Sim T, Tae JS, and Lee SH. 2015. Optimization of Bipyridinyl Pyrazole Scaffolds via Design, Synthesis and Screening of a New Series of ROS1 Kinase-modulating Compounds. *Bulletin of the Korean Chemical Society* 36:305-311.

Cee VJ, Chen DYK, Lee MR, and Nicolaou KeC. 2009. Cortistatin A is a High-Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11. *Angewandte Chemie International Edition* 48:8952-8957.

Chen W, Ren X, and Chang CeA. 2019. Discovery of CDK8/CycC Ligands with a New Virtual Screening Tool. *ChemMedChem* 14:107-118.

Crown J. 2017. CDK8: a new breast cancer target. *Oncotarget* 8:14269.

Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, and Ogino S. 2008. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. *Nature* 455:547.

He L-J, Zhu Y-B, Fan Q-Z, Miao D-D, Zhang S-P, Liu X-P, and Zhang C. 2019. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes. *Bioorganic & medicinal chemistry letters* 29:549-555.

Inc. CCG. 2016. Molecular operating environment (MOE). Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal ....

Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, Menendez S, Vardabasso C, LeRoy G, and Vidal Cl. 2010. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. *Nature* 468:1105.

Kim S, Xu X, Hecht A, and Boyer TG. 2006. Mediator is a transducer of Wnt/β-catenin signaling. *Journal of Biological Chemistry* 281:14066-14075.

Knuesel MT, Meyer KD, Bernecky C, and Taatjes DJ. 2009a. The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. *Genes & development* 23:439-451.

Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, and Taatjes DJ. 2009b. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. *Molecular and cellular biology* 29:650-661.

Li J, Li X, Kong X, Luo Q, Zhang J, and Fang L. 2014a. MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. *International journal of clinical and experimental medicine* 7:558.

Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, and Shaik S. 2014b. Cyclin C is a haploinsufficient tumour suppressor. *Nature cell biology* 16:1080.

Malik S, and Roeder RG. 2005. Dynamic regulation of pol II transcription by the mammalian Mediator complex. *Trends in biochemical sciences* 30:256-263.

McDermott MS, Chumanevich AA, Lim C-u, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shultman M, and Kiaris H. 2017. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. *Oncotarget* 8:12558.

Medapi B, Suryadevara P, Renuka J, Sridevi JP, Yogeeswari P, and Sriram D. 2015. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: structural optimization, synthesis and biological evaluation. *European journal of medicinal chemistry* 103:1-16.

Nemet J, Jelicic B, Rubelj I, and Sopta M. 2014. The two faces of Cdk8, a positive/negative regulator of transcription. *Biochimie* 97:22-27.

Obaya A, and Sedivy JM. 2002. Regulation of cyclin-Cdk activity in mammalian cells. *Cellular and Molecular Life Sciences* CMLS 59:126-142.
trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors. *Bioorganic & medicinal chemistry* 22:3871-3878.

Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefov A, Fadeyi O, and Christie AL. 2015. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. *Nature* 526:273.

Rivilli MJL, Turina AV, Bignante EA, Molina VH, Perillo MA, Briñon MC, and Moyano EL. 2018. Synthesis and pharmacological evaluation of pyrazolo [4, 3-c] quinolinones as high affinity GABAA-R ligands and potential anxiolytics. *Bioorganic & medicinal chemistry* 26:3967-3974.

Roninson IB, Győrffy B, Mack ZT, Shtil AA, Shtutman MS, Chen M, and Broude EV. 2019. Identifying cancers impacted by CDK8/19. *Cells* 8:821.

Rzymski T, Mikula M, Wiklik K, and Brzózka K. 2015. CDK8 kinase—An emerging target in targeted cancer therapy. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics* 1854:1617-1629.

Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K, Masiejczyk M, Wróbel A, and Dolata I. 2017. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. *Oncotarget* 8:33779.

Sánchez-Martínez C, Lallena MJ, Sanfeliciano SG, and de Dios A. 2019. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). *Bioorganic & medicinal chemistry letters*:126637.

Satyanarayana A, and Kaldis P. 2009. Mammalian cell-cycle regulation: several Cdns, numerous cyclins and diverse compensatory mechanisms. *Oncogene* 28:2925.

Schiemann K, Mallinger A, Wienke D, Esdar C, Poerschke O, Busch M, Rohdich F, Eccles SA, Schneider R, and Raynaud Fl. 2016. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. *Bioorganic & medicinal chemistry letters* 26:1443-1451.

Schneider E, Böttcher J, Blaesse M, Neumann L, Huber R, and Maskos K. 2011. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. *Journal of molecular biology* 412:251-266.

Schneider EV, Böttcher J, Huber R, Maskos K, and Neumann L. 2013. Structure–kinetic relationship study of CDK8/CycC specific compounds. *Proceedings of the National Academy of Sciences* 110:8081-8086.

Sears RC, and Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. *Journal of Biological Chemistry* 277:11617-11620.

Xu W, and Ji J-Y. 2011. Dysregulation of CDK8 and Cyclin C in tumorigenesis. *Journal of Genetics and Genomics* 38:439-452.
Figure 1

A: Predicted 2D presentation of ligand binding modes of compound 5d in the kinase domain of CDK8/CycC active pocket. B: Predicted 3D presentation of ligand binding pose of 5d in the active site of CDK8/CycC from the crystal structure 4F7S.

Discovery Studio Visualizer prepared 3D presentation by which the interacting residues are shown in lines; dotted lines are used to visualize the protein-ligand interactions.
Figure 2

Synthesis of target quinolines 5a-i

Reagents and conditions: (i) Diethyl ethoxymethylenemalonate / Ethanol / reflux 1hr; (ii) Diphenyl ether / 250 °C / 45 min; (iii) POCl₃ / reflux 1hr; (iv) Absolute ethanol/ reflux 4hr.
Table 1 (on next page)

Inhibition data of CDK8/CycC for compounds 5a-i using Staurosporine as a standard inhibitor.
Table 1. Inhibition data of CDK8/CycC for compounds 5a-i, using Staurosporine as a standard inhibitor.

| Comp. | R   | R'       | % enzyme inhibition ± SD (20 µM) | IC50 (µM) |
|-------|-----|----------|---------------------------------|-----------|
| 5a    | 6-Br| SO2NH2   | 83.91 ± 1.83                    | 3.98      |
| 5b    | 6-OCH3| SO2NH2  | 63.365 ± 2.31                  | 5.34      |
| 5c    | 7-Cl-6-F| SO2NH2  | 37.925 ± 1.31                  | No inhibition |
| 5d    | 6-Br| NHSO2CH3 | 88.59 ± 0.97                    | 0.639     |
| 5e    | 6-OCH3| NHSO2CH3 | 85.875 ± 0.94                  | 1.42      |
| 5f    | 7-Cl-6-F| NHSO2CH3 | 27.225 ± 8.46                  | No inhibition |
| 5g    | 6-Br| SO2NHCH3 | 22.425 ± 1.02                  | No inhibition |
| 5h    | 6-OCH3| SO2NHCH3 | 18.655 ± 0.48                  | No inhibition |
| 5i    | 7-Cl-6-F| SO2NHCH3 | 31.96 ± 0.82                  | No inhibition |
| Staurosporine |       |          | 1.00 E-4                        |           |